P
ProHub
English 简体中文 繁體中文
BCG Hard Cost Reduction

BioPharma LOE

#Bio-Pharma
ProHub Comment

This case requires candidates to conduct external benchmarking, identify cost overruns through comparative analysis, and develop a targeted cost reduction strategy. The case emphasizes both quantitative analysis (comparing IT spend ratios across competitors) and qualitative judgment (assessing which functions are candidates for outsourcing vs. requiring in-house expertise).

Estimated Time 37 minutes
Difficulty Hard
Source Duke
38 / 100
Fuqua & Co. is a global BioPharma firm. In 2009, they acquired a smaller player, Kenan-Flagler Co., for $41B. The key driver was a breakthrough oncology drug, KeyChapel, the first of its kind to selectively target and kill cancer cells. The acquisition proved far more successful than anticipated. While Fuqua & Co. expected KeyChapel to generate about $10B in annual sales, the drug has grown to produce ~$40B annually, making Fuqua & Co. the second largest BioPharma company in the world. KeyChapel’s loss of exclusivity (LOE) is expected in January 2028. At that point, Fuqua & Co. projects a 50% drop in revenues, which would severely impact their business. The client is scrambling to prepare for this shift and has engaged us to help. They have asked us to evaluate how they can right size their operation.

Clarifying Information

  1. Business Model: Client sells KeyChapel, the only proven drug on the market that kills cancer cells, as well as an HPV vaccine that has seen shrinking market share domestically and abroad that accounts for 20% of revenues, and a few other drugs making up the remaining revenue.
  2. Objective: Client wants to benchmark their organizational health against their competitors and use this information to target areas for cost reductions. They want to reduce costs by $4.5B before the LOE for KeyChapel.
Mock Interview
Interviewer

Fuqua & Co. is a global BioPharma firm. In 2009, they acquired a smaller player, Kenan-Flagler Co., for $41B. The key driver was a breakthrough oncology drug, KeyChapel, the first of its kind to selectively target and kill cancer cells. The acquisition proved far more successful than anticipated. While Fuqua & Co. expected KeyChapel to generate about $10B in annual sales, the drug has grown to produce ~$40B annually, making Fuqua & Co. the second largest BioPharma company in the world. KeyChapel's loss of exclusivity (LOE) is expected in January 2028. At that point, Fuqua & Co. projects a 50% drop in revenues, which would severely impact their business. The client is scrambling to prepare for this shift and has engaged us to help. They have asked us to evaluate how they can right size their operation.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

Fuqua & Co., facing a 50% revenue drop from KeyChapel’s loss of exclusivity in 2028, must reduce costs by $4.5B. Through benchmarking against competitors, the case reveals IT spending is 2.4x the industry average. The solution involves outsourcing specific IT job families (Data & Analytics and Software Engineering) across Enterprise, R&D, and Human Health departments to achieve approximately $4.4B in savings.

Key Insights:

  1. External benchmarking reveals the client’s IT spend is 2.4x industry average ($16B vs. ~$6.7B average), indicating structural inefficiency rather than temporary overages
  2. Not all cost categories are equally suitable for outsourcing—Risk IT and compliance functions require in-house expertise due to regulatory/security sensitivity
  3. The case requires distinguishing between different IT job families’ outsourcing potential; Data & Analytics and Software Engineering offer 50-75% savings potential while Infrastructure and Support have lower potential
  4. Successful cost reduction requires considering transition costs, vendor RFP evaluation, and change management to validate net savings against implementation risks